Logo (WIPO, 07/09/2018)
WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark was filed as Figurative mark on 07/09/2018 at the World Intellectual Property Organization.
Logodesign (Wiener Klassifikation)
#Circles #Quadrilaterals #Other geometrical figures, indefinable designs #Several circles, juxtaposed, tangential or intersecting #Rhombs or squares standing on one of the corners thereof
| Trademark form | Figurative mark |
| File reference | 1446911 |
| Countries | 
|
| Base trademark |
No. ,
September 6, 2024
|
| Application date | July 9, 2018 |
| Expiration date | July 9, 2028 |
Trademark owner
4504 Emperor Blvd.
Durham NC 27703
US
Durham NC 27703
US
Trademark representatives
Prudential Tower,
800 Boylston Street
US
goods and services
05
Pharmaceuticals for the treatment of infectious, viral
inflammatory, immunological, autoimmune and cardiovascular
diseases and disorders; pharmaceuticals for the treatment of
hereditary angioedema, inflammatory bowel diseases,
inflammatory connective tissue diseases and inflammatory
skin diseases; pharmaceuticals for the treatment of
influenza, AIDS, SARS, Ebola, Zika, and West Nile virus;
pharmaceuticals for the treatment of transplant rejection;
anti-infective pharmaceuticals; pharmaceuticals for the
treatment of cancer, namely, cancers of the immune system
such as T-cell and B-cell leukemias and lymphomas
42
Pharmaceutical research and drug development; medical and
scientific research, namely, conducting clinical trials for
others, development of pharmaceuticals for the treatment of
infectious, viral, inflammatory, immunological, autoimmune
and cardiovascular diseases and disorders; development of
pharmaceuticals for the treatment of cancer, namely, cancers
of the immune system such as T-cell and B-cell leukemias and
lymphomas; development of pharmaceuticals for the treatment
of influenza, AIDS, SARS, Ebola, Zika, and West Nile virus;
development of pharmaceuticals for the treatment of
hereditary angioedema, inflammatory bowel diseases,
inflammatory connective tissue diseases and inflammatory
skin diseases
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| October 25, 2022 | 2022/43 Gaz | PH | RAW: Total Invalidation |
| March 11, 2022 | 2022/17 Gaz | US | RAW: Partial Ceasing Effect |
| December 19, 2020 | 2021/1 Gaz | PH | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| July 2, 2020 | 2020/28 Gaz | TH | Rejection |
| April 2, 2020 | 2020/15 Gaz | IL | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| February 27, 2020 | 2020/9 Gaz | JP | Rejection |
| January 21, 2020 | 2020/4 Gaz | VN | Rejection |
| January 10, 2020 | 2020/3 Gaz | NO | Rejection |
| January 6, 2020 | 2020/2 Gaz | KR | Rejection |
| December 11, 2019 | 2019/50 Gaz | CH | Rejection |
| December 2, 2019 | 2019/50 Gaz | IN | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| November 12, 2019 | 2019/46 Gaz | ID | Rejection |
| October 2, 2019 | 2019/40 Gaz | CO | Rejection |
| September 13, 2019 | 2019/52 Gaz | MX | Rejection |
| August 13, 2019 | 2019/34 Gaz | IL | Rejection |
| August 13, 2019 | 2019/33 Gaz | AU | Rejection |
| July 30, 2019 | 2019/31 Gaz | NZ | Rejection |
| July 11, 2019 | 2019/28 Gaz | SG | Rejection |
| July 2, 2019 | 2019/28 Gaz | RU | Rejection |
| July 2, 2019 | 2019/27 Gaz | EM | Rejection |
| March 29, 2019 | 2019/14 Gaz | CN | Rejection |
| February 14, 2019 | 2019/8 Gaz | PH | Rejection |
| February 11, 2019 | 2019/8 Gaz | IN | Rejection |
| July 9, 2018 | 2019/3 Gaz | US | Registration |
ID: 141446911